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BACKGROUND: High-risk human papilloma viruses (HPVs) are candidates as causal viruses in breast cancer. The scientific challenge is to
determine whether HPVs are causal and not merely passengers or parasites. Studies of HPV-related koilocytes in breast cancer offer
an opportunity to address this crucial issue. Koilocytes are epithelial cells characterised by perinuclear haloes surrounding condensed
nuclei and are commonly present in cervical intraepithelial neoplasia. Koilocytosis is accepted as pathognomonic (characteristic of a
particular disease) of HPV infection. The aim of this investigation is to determine whether putative koilocytes in normal and malignant
breast tissues are because of HPV infection.
METHODS: Archival formalin-fixed normal and malignant breast specimens were investigated by histology, in situ PCR with confirmation
of the findings by standard PCR and sequencing of the products, plus immunohistochemistry to identify HPV E6 oncoproteins.
RESULTS: human papilloma virus-associated koilocytes were present in normal breast skin and lobules and in the breast skin and cancer
tissue of patients with ductal carcinoma in situ (DCIS) and invasive ductal carcinomas (IDCs).
INTERPRETATION: As koilocytes are known to be the precursors of some HPV-associated cervical cancer, it follows that HPVs may be
causally associated with breast cancer.
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High-risk human papilloma viruses (HPVs) are candidates as
causal viruses in breast cancer (Lawson et al, 2006). Human
papilloma virus high-risk types 16, 18 and 33 have been identified
in breast cancers from 15 widely different populations (Lawson
et al, 2006). The scientific challenge is to determine whether HPVs
are causal and not merely passengers or parasites.
Studies of HPV-related koilocytes in breast cancer offer an
opportunity to address this crucial issue. Koilocytes are commonly
present in cervical intraepithelial neoplasia. They are epithelial
cells characterised by perinuclear haloes (cytoplasmic vacuolation)
surrounding condensed nuclei (Ayre, 1951; Koss and Durfee,
1956). Koilocytosis is accepted as pathognomonic (characteristic of
a particular disease) of HPV infection (Reid et al, 1982). These
early findings have been repeatedly confirmed with modern
techniques (Roteli-Martins et al, 2001; Krawczyk et al, 2008).
Koilocytosis is a key indicator of subclinical HPV infection and
early HPV-associated morphological changes may be used as part
of ‘Pap’ screening for cervical cancer (Abadi et al, 1998).
Putative (supposed) HPV-associated koilocytes have been
observed in some breast neoplasias (de Villiers et al, 2005).
There is a biological continuum linking signs of HPV infection
leading to koilocytosis, cervical intraepithelial neoplasia and
cervical cancer (Reid et al, 1984). Forty-eight per cent of women
with koilocytosis alone in cervical epithelial cells may develop
cervical intraepithelial neoplasia (Evans-Jones et al, 1985).
The mechanisms by which high-risk HPV infections cause
cervical cancer have been studied in detail (Zur Hausen, 2002). In
this study, we have used HPV-associated cervical cancer as a
model. High-risk HPV encodes a series of proteins, some of which
have oncogenic potential. Human papilloma virus proteins are
designated as early (E1–E7) or late (L1 and L2). E5 and E6 act
early in transformation (before integration) and are known to
disrupt cytokeratin-causing perinuclear cytoplasmic clearing and
nuclear enlargement, which leads to the appearance of a koilocyte
(Krawczyk et al, 2008). E6 and E7 oncoproteins work in concert to
disrupt cell cycle regulation and stimulate cell cycle progression by
binding and inhibiting the p53 and p110
RB tumour suppressor
genes, respectively, thereby inducing the proliferation of infected
basal cells, which facilitates replication of the viral genome. By
binding to and degrading the apoptosis-inducing p53 protein,
E6 also inhibits cell death (apoptosis). E7-induced degradation of
p110
RB often results in a reciprocal overexpression of the cyclin-
dependent kinase inhibitor p16
INK4A, although this is further
complicated with increasing cancer stage.
Increasing levels of HPV viral load seem to be associated with an
increased risk of developing cervical pre-cancer (Winer et al,
2009). This is relevant to HPV-associated breast cancer as the viral
load in cervical cancer seems to be over 4000 times higher than in
breast cancer (Fiander et al, 2007; Khan et al, 2008). This huge
difference possibly explains the relatively brief time between
HPV infection and precancerous changes in the cervix
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s(within 12 months) as compared with the presumed long time
between HPV infections and the diagnosis of breast cancer. The
extremely low viral load is the probable reason for the considerable
difficulty in detection of HPV in breast cancers (Kan et al, 2005).
Whether koilocytosis is related to breast cancer development is not
known.
Koilocytosis in various HPV-associated cancers and benign
lesions.
Putative koilocytes have been identified in HPV 6/11-associated
benign laryngeal papillomas (Martins et al, 2008), high-risk HPV
16-associated malignant oesophageal lesions (Miller et al, 1997),
high-risk HPV 11-associated conjunctival papilloma (Minchiotti
et al, 2006), HPV 6/11-associated benign ductal papillomas of the
salivary glands (Haberland-Carrodeguas et al, 2003), and high-risk
HPV 16 in bladder cancers (Aggarwal et al, 2009). These
associations between the presence of HPVs and koilocytosis are
in addition to their well-established associations in anogenital
cancers (Boon and Kok, 1985).
Pseudo-koilocytes
The diagnosis of koilocytosis has traditionally been based on
histological features. Over the years, definitions of koilocytosis
have evolved and, as a consequence, excess diagnosis of
cervical koilocytosis (positive histological features with
negative HPV genetic material) is a problem (Abadi et al, 1998).
Therefore, investigations of HPV-associated koilocytosis in
breast cancer need to include biological assessments in addition
to histology.
MATERIALS AND METHODS
We investigated the possible presence of koilocytes in normal and
malignant breast specimens. Archival formalin-fixed invasive
ductal carcinoma (IDCs) and ductal carcinoma in situ (DCIS)
specimens plus normal breast specimens from cosmetic surgery
were used.
PCR is by far the most sensitive technique available for the
identification of extremely low viral loads, but the technique is
associated with problems including both false negatives and false
positives, contamination and inconsistent outcomes (Teo and
Shaunak, 1995). For this reason, we used both standard and in situ
PCR together with known positive and negative controls. In
addition, we used immunohistochemistry to identify the presence
of HPV types 16 and 18 E6 oncoprotein again with both positive
and negative controls. We eliminated samples that potentially
could give false-positive HPV results, identified by positive in situ
PCRs without primers. An unknown number of these eliminated
specimens would have been true positives. Accordingly, the data
cannot be used to make estimates of prevalence of the presence of
these viruses.
The methods used for both standard PCR (using DNA extracted
from formalin-fixed archival breast cancer specimens) and in situ
PCR conducted on the same specimens are as described in detail in
our companion paper (Heng et al, 2009).
Histology
We based simplified histological definitions of koilocytosis on
those established by Reid et al (1982) as follows:
1. Koilocytic cytoplasmic vacuolisation: perinuclear haloes
surrounding cell nuclei.
2. Koilocytic nuclear change: pyknosis – nuclear material that may
be irregular in size, shape and staining properties. The nucleus
is frequently acentric. Binucleation may be apparent. It is now
known that ‘binucleation’ involves multilobules caused by
HPV-influenced activity at the G2 cell cycle checkpoint
(Cho et al, 2005). In simple terms, large cells with perinuclear
clearing take up a majority of the cells with associated
nuclear atypia.
We compared the breast cancer and normal breast specimens that
contained koilocytes with cervical cancer specimens that also
contained koilocytes.
Immunohistochemistry
We used standard immunohistochemistry techniques to assess
the expression of HPV types 16 and 18 E6 oncoprotein. Human
papilloma virus type 16/18 E6 – abCam (ab70) commercial
antibodies were used. Human papilloma virus E6 is a nuclear,
cytoplasmic and membrane stain. Positive (HPV-positive cervical
cancer specimen) and negative (HPV E6 antibody omitted)
controls were used.
RESULTS
Putative (supposed) HPV-associated koilocytes were present in
normal breast skin and lobules and in the breast skin and cancer
tissue of patients with DCIS and IDCs. These data are shown in
Table 1. The identification of koilocytes was determined by the
presence of a halo or vacuole in the cell cytoplasm surrounding the
nucleus. Pyknosis (intensely stained and irregularly shaped nuclei)
was identified in a majority but not all of the putative koilocytes.
Some of the specimens were mixed DCIS and IDCs. For reasons of
clarity, if invasive characteristics were present, the specimen was
classified as IDC.
Putative koilocytosis in normal breast lobules and nipple skin
of the same subject is shown in Figure 1. This specimen of
normal breast tissue was obtained from a normal woman who had
cosmetic surgery. Human papilloma virus 18 was identified by
in situ PCR in the breast lobules and koilocytes of this
same specimen. Human papilloma virus oncoprotein E6 is present
in the basal layers of breast skin and in the intercellular spaces
and cytoplasm of koilocytes, normal breast epithelial cells
and malignant cells. There is little E6 nuclear staining. In
some specimens stained for HPV E6, there is ‘background’
staining (Figures 1–3). The identification of HPV 16 and 18 was
confirmed by sequencing the products of standard PCR in a
limited number of the specimens. These sequencing data have
been reported in the companion paper (Heng et al, 2009).
Putative koilocytosis, positive for HPV by in situ PCR and HPV
E6 oncoprotein in DCIS, is shown in Figure 2 and greatly enlarged
in Figure 3.
Table 1 The presence of HPV in normal breast, DCIS and IDC
specimens
HPV by in situ PCR
a
(types 16 and 18)
HPV by standard PCR
a
(types 16 and 18)
Normal breast
b 4/18 (22.2%) —
DCIS
b 4/12 (33.3%) 4/10 (40.0%)
IDC
b 4/9 (44.4%) 3/4 (75.0%)
aHPV identified in normal breast, DCIS and IDC specimens by in situ PCR confirmed
by standard PCR and sequencing of the product as previously reported (Heng et al,
2009).
bThe differences in numbers of specimens is because of exclusion of
potentially false-positive PCR analyses and poor-quality sections damaged during
processing.
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sDISCUSSION
The presence of HPV-associated koilocytes in normal breast
lobules and skin and in DCIS and IDC breast cancer has been
shown.
Validity of the evidence
The viral load of the HPV genome in breast tumours is known
from a study based on Japanese subjects in Japan to be extremely
low (Khan et al, 2008). Although data based solely on Japanese
experience cannot be generalised, we and others have had
considerable difficulty in the identification of HPV in both fresh
and fixed breast cancer specimens from Australian and other
Western women (Kan et al, 2005). For this reason, we have used
both standard and in situ PCR plus immunohistochemistry in this
investigation. We also used standard criteria for the histological
characteristics of koilocytes. We believe the data to be valid
because of the confirmation that HPV sequences are present in
koilocytes by in situ PCR with confirmation by sequencing of the
product of standard PCR extracted from the same specimen.
The pattern of HPV E6 staining mainly in the cell cytoplasm and
the intercellular spaces is of interest as this same pattern of
staining has been observed in cervical tissue lesions (mainly
lymphocytes) when stained with the same antibodies (abCam 70)
(Kobayashi et al, 2002). This adds to the validity of our current
observations.
The possible mechanics of HPV transmission in breast cancer is
of interest as it is commonly assumed that cell surface-to-surface
contact, mainly during sexual activities, is required. It is possible
that there may be initial surface-to-surface cell contact with HPV
virions that are expressed by desquamating cells during sexual
intercourse followed by transmission through the blood or
lymphatic systems (Pao et al, 1991; Bryan and Brown, 2001). The
transmission of HPV infections by oral sexual activities has
recently been shown and is also a possible transmission route for
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Figure 1 Normal breast specimen. Breast lobules and breast skin showing HPV-associated koilocytes, HPV E6 oncoprotein expression and HPV type 18
by in situ PCR in koilocyte nuclei. (A) Breast skin with koilocytes (H & E stain), (B) breast skin from the same subject showing koilocytes and HPV E6
oncoprotein expression in the basal layers of the skin (immunohistochemistry), (C) breast lobules from the same subject with koilocytes (H & E stain),
(D) breast lobules from the same specimen with HPV E6 oncoprotein expression plus koilocytes (immunohistochemistry), (E) positive HPV type 18
expression in the nuclei of koilocytes in the same specimen by in situ PCR, (F) negative HPV expression in the same specimen by in situ PCR with primers
omitted (control analysis). The arrows indicate selected putative koilocytes.
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Figure 2 Putative koilocytes in a ductal carcinoma in situ breast cancer specimen. (A) H & E stain, (B) HPV E6 oncoprotein by immunohistochemistry,
(C) in situ PCR for HPV type 18 showing positive staining in the putative koilocytes, (D) negative control omitting primers from the in situ PCR. The arrows
indicate selected putative koilocytes.
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Figure 3 Human papilloma virus (HPV) 16/18 E6 staining in normal and ductal carcinoma in situ (DCIS) breast cancer specimens.
(A) H & E stain of normal breast skin specimen (enlarged version of Figure 1A), (B) HPV-E6 oncoprotein by immunohistochemistry of normal breast
skin specimen (enlarged version of Figure 1B), (C) haematoxylin stain, with eosin omitted, of DCIS specimen (enlarged version of Figure 2A), (D) HPV-E6
oncoprotein by immunohistochemistry of DCIS specimen (enlarged version of Figure 2B). The HPV E6 staining (orange colour) in panels B and D
appears in the intercellular spaces, some nuclei, cytoplasm and possibly the surface of the cell membranes of the koilocytes. The arrows indicate selected
putative koilocytes.
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sHPVs in breast cancer (D’Souza et al, 2009). Transmission of high-
risk HPVs is also possible without sexual activity as has been
shown in families from Finland (Rintala et al, 2005).
The mechanics of the specific association between HPV
infections and koilocytosis has recently been shown (Krawczyk
et al, 2008). Koilocytosis may be present as a consequence of
infections by both low- and high-risk HPVs. The early HPV
proteins designated E5 and E6 cooperate to produce koilocytes in
cervical cells.
As the HPV viral load in breast cancer seems to be extremely
low, the oncogenic influences of HPVs are likely to be less than in
cervical and other anogenital cancers. Therefore, it should not be
assumed that the presence of koilocytosis in normal breast tissues
commonly leads to breast cancer. Human papilloma virus
infections may well be common in the breast, but consequent
cancer may be rare.
For the following reasons, we believe it is likely that high-risk
HPVs may have an aetiological role in some breast cancers:
(i) HPV infections are specifically associated with koilocytosis in
cervical and other tissues, (ii) HPVs have been repeatedly
identified in breast cancers that have occurred in women from a
wide range of populations, (iii) HPV-positive koilocytes are
present in normal skin and breast tissues of normal women,
(iv) HPV-positive koilocytes are present in many DCIS and some
IDC specimens. As HPV-associated koilocytes in the cervix
may progress to varying grades of malignancy (Thomison et al,
2008), it follows that HPV may be causally associated with
breast cancer.
Infections of the cervix by HPV types 16 and 18, as identified in
these investigations, are successfully inhibited by the new anti-
HPV vaccines (Rambout et al, 2007; Koutsky, 2009). It is likely that
the same HPV types infecting the breast will also be inhibited by
these vaccines and, for the first time, offer primary prevention of
some breast cancers.
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